Hexim-1 modulates androgen receptor and the TGF-β signaling during the progression of prostate cancer

Prostate

Volumn 72, Issue 9, 2012, Pages 1035-1044

  Mascareno, Eduardo J ^a   Belashov, Ivan ^b   Siddiqui, M A Q ^a   Liu, Fang ^c   Dhar Mascareno, Manya ^b  

^a SUNY Downstate Medical Center   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

androgen receptor; HEXIM1; mouse model; prostate cancer; RNA polymerase; serine phosphorylation; SMAD phosphorylation; TGF

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN DEPENDENT KINASE 9; HEXAMETHYLENE BISACETAMIDE INDUCIBLE PROTEIN 1; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERINE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE; HETEROZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ANIMALS; DISEASE PROGRESSION; HUMANS; MALE; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84861096474     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21510     Document Type: Article

References (49)

1. Hsieh AC, Small EJ, Ryan CJ,. Androgen-response elements in hormone-refractory prostate cancer: Implications for treatment development. Lancet Oncol 2007; 8 (10): 933-939.
2. Dehm SM, Tindall DJ,. Androgen receptor structural and functional elements: Role and regulation in prostate cancer. Mol Endocrinol 2007; 21 (12): 2855-2863.
3. Brooke GN, Bevan CL,. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009; 10 (1): 18-25.
4. Chen G, Wang X, Zhang S, Lu Y, Sun Y, Zhang J, Li Z, Lu J,. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 2005; 63 (4): 395-406.
5. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC,. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005; 8 (2): 108-118.
6. Stiles B, Groszer M, Wang S, Jiao J, Wu H,. PTENless means more. Dev Biol 2004; 273 (2): 175-184.
7. Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D,. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: A promising therapeutic approach. Clin Cancer Res 2004; 10 (24): 8728-8734.
8. Choy M, Rafii S,. Role of angiogenesis in the progression and treatment of prostate cancer. Cancer Invest 2001; 19 (2): 181-191.
9. Sun Y, Niu J, Huang J,. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009; 1 (2): 148-162.
10. Montano X, Djamgoz MB,. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett 2004; 571 (1-3): 1-8.
11. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM,. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007; 120 (4): 719-733.
12. Zhu ML, Kyprianou N,. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15 (4): 841-849.
13. Berry PA, Maitland NJ, Collins AT,. Androgen receptor signalling in prostate: Effects of stromal factors on normal and cancer stem cells. Mol Cell Endocrinol 2008; 288 (1-2): 30-37.
14. Dey A, Chao SH, Lane DP,. HEXIM1 and the control of transcription elongation: From cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle 2007; 6 (15): 1856-1863.
15. Shilatifard A,. Factors regulating the transcriptional elongation activity of RNA polymerase II. FASEB J 1998; 12 (14): 1437-1446.
16. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q,. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell 2003; 12 (4): 971-982.
17. Dames SA, Schonichen A, Schulte A, Barboric M, Peterlin BM, Grzesiek S, Geyer M,. Structure of the Cyclin T binding domain of Hexim1 and molecular basis for its recognition of P-TEFb. Proc Natl Acad Sci USA 2007; 104 (36): 14312-14317.
18. Lee DK, Chang C,. Molecular communication between androgen receptor general transcription machinery. J Steroid Biochem Mol Biol 2003; 84 (1): 41-49.
19. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ, Sapkota G, Pan D, Massague J,. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009; 139 (4): 757-769.
20. Matsuura I, Chiang KN, Lai CY, He D, Wang G, Ramkumar R, Uchida T, Ryo A, Lu K, Liu F,. Pin1 promotes transforming growth factor-beta-induced migration and invasion. J Biol Chem 285 (3): 1754-1764.
21. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM,. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92 (8): 3439-3443.
22. Huang F, Wagner M, Siddiqui MA,. Ablation of the CLP-1 gene leads to down-regulation of the HAND1 gene and abnormality of the left ventricle of the heart and fetal death. Mech Dev 2004; 121 (6): 559-572.
23. Mascareno E, Beckles D, Dhar-Mascareno M, Siddiqui MA,. Enhanced hypertrophy in ob/ob mice due to an impairment in expression of atrial natriuretic peptide. Vascul Pharmacol 2009; 51 (2-3): 198-204.
24. Kretzschmar M, Doody J, Timokhina I, Massague J,. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 1999; 13 (7): 804-816.
25. Espinoza-Derout J, Wagner M, Salciccioli L, Lazar JM, Bhaduri S, Mascareno E, Chaqour B, Siddiqui MA,. Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1. Circ Res 2009; 104 (12): 1347-1354.
26. Dirim A, Haberal AN, Goren MR, Tekin MI, Peskircioglu L, Demirhan B, Ozkardes H,. VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value. Int Urol Nephrol 2008; 40 (4): 861-868.
27. Garriga J, Grana X,. Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene 2004; 337: 15-23.
28. Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC, Conaway M, Carey MF, Gioeli D,. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol 24 (12): 2267-2280.
29. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM,. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57 (16): 3325-3330.
30. Qiu P, Feng XH, Li L,. Interaction of Smad3 and SRF-associated complex mediates TGF-beta1 signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 2003; 35 (12): 1407-1420.
31. Rho JH, Roehrl MH, Wang JY,. Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res 2009; 8 (12): 5610-5618.
32. Pang J, Liu WP, Liu XP, Li LY, Fang YQ, Sun QP, Liu SJ, Li MT, Su ZL, Gao X,. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res; 9 (1): 216-226.
33. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH,. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28 (1): 92-98.
34. Kennedy RD, Quinn JE, Johnston PG, Harkin DP,. BRCA1: Mechanisms of inactivation and implications for management of patients. Lancet 2002; 360 (9338): 1007-1014.
35. Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, Ford M, Crawford M, Urban N, O'Briant K, Nelson BH,. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer 2003; 104 (1): 73-84.
36. Wittmann BM, Fujinaga K, Deng H, Ogba N, Montano MM,. The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. Oncogene 2005; 24 (36): 5576-5588.
37. Turano M, Napolitano G, Dulac C, Majello B, Bensaude O, Lania L,. Increased HEXIM1 expression during erythroleukemia and neuroblastoma cell differentiation. J Cell Physiol 2006; 206 (3): 603-610.
38. Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J, Kanwal C, DePinto W, Rosinski J, McLoughlin P, Ritland S, DeMario M, Tobon K, Reidhaar-Olson JF, Rueger R, Hilton H,. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Mol Cancer Ther 2009; 8 (9): 2517-2525.
39. Diribarne G, Bensaude O,. 7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor. RNA Biol 2009; 6 (2): 122-128.
40. Ouchida R, Kusuhara M, Shimizu N, Hisada T, Makino Y, Morimoto C, Handa H, Ohsuzu F, Tanaka H,. Suppression of NF-kappaB-dependent gene expression by a hexamethylene bisacetamide-inducible protein HEXIM1 in human vascular smooth muscle cells. Genes Cells 2003; 8 (2): 95-107.
41. Shimizu N, Ouchida R, Yoshikawa N, Hisada T, Watanabe H, Okamoto K, Kusuhara M, Handa H, Morimoto C, Tanaka H,. HEXIM1 forms a transcriptionally abortive complex with glucocorticoid receptor without involving 7SK RNA and positive transcription elongation factor b. Proc Natl Acad Sci USA 2005; 102 (24): 8555-8560.
42. Ogba N, Chaplin LJ, Doughman YQ, Fujinaga K, Montano MM,. HEXIM1 regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of cyclin D1 in mammary cells via modulation of P-TEFb. Cancer Res 2008; 68 (17): 7015-7024.
43. Gurumurthy M, Tan CH, Ng R, Zeiger L, Lau J, Lee J, Dey A, Philp R, Li Q, Lim TM, Price DH, Lane DP, Chao SH,. Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. J Mol Biol 2008; 378 (2): 302-317.
44. Dobrovolskaia MA, Kozlov SV,. Inflammation and cancer: When NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets 2005; 5 (5): 325-344.
45. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D,. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6 (6): 703-706.
46. Lee DK, Duan HO, Chang C,. Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation. J Biol Chem 2001; 276 (13): 9978-9984.
47. Kesler CT, Gioeli D, Conaway MR, Weber MJ, Paschal BM,. Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. Mol Endocrinol 2007; 21 (9): 2071-2084.
48. van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, Dubbink HJ, Verschure PJ, Trapman J, Houtsmuller AB,. Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol 2007; 177 (1): 63-72.
49. Massague J,. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1 (3): 169-178.